Average Years of Potential Life Lost in Those Who Have Died from Brain and CNS Tumors in the USAThuppal S. · Propp J.M. · McCarthy B.J.
University of Illinois at Chicago, Chicago, Ill., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The aim of this study was to quantify the impact of all primary malignant and nonmalignant brain and central nervous system (CNS) tumors on mortality in the USA in terms of years of life lost, an indicator of premature mortality in the population. In this study, US mortality data for the year 2001 from the National Center for Health Statistics and life tables from the US Census Bureau were used. Person-years of potential life lost (PYPLL) and average years of potential life lost (AYPLL) were calculated for all deaths due to brain and CNS tumors as an underlying cause. 16,819 deaths due to brain and CNS tumors occurred in 2001, leading to a total loss of 357,483 person-years of life and an average loss of 21.3 years (AYPLL). Hispanic men and women had an AYPLL of 31.7 and 33.9 years, respectively, a figure substantially higher than other race and ethnicity categories. Malignant tumors led to an AYPLL of 25 years, which was significantly higher than the AYPLL of 19 years due to nonmalignant tumors. The relative impact of tumors arising in the various anatomical sites in the brain and CNS among adults and among children was not similar. The use of population survival indicators, such as PYPLL and AYPLL, will help better understanding of the effect of racial, ethnic, gender and age differences on the mortality due to malignant and nonmalignant brain and CNS tumors. Information on years of life lost, as well as mortality data, will be useful in focusing research priorities and resources in this field.
© 2006 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.